Table 1 Participant demographics and clinical information during study period
Variable | Number |
|---|---|
Number of participants | 19 |
Age at first visit, median years (min, max) | 3.20 (0.23, 8.75) |
Female, n (%) | 10 (53%) |
Aboriginal or Torres Strait Islander, n (%) | 19 (100%) |
Vaccination status, n (%) | |
 Up to date | 14 (74%) |
 Unknown | 5 (26%) |
Number of participants with > 1 timepoint, n (%) | 14 (74%) |
Number of visits with swabs collected, median (min, max) | 2 (1, 7) |
Days between first and last swab (in those with > 1 timepoint), median (min, max) | 485 (150, 730) |
Participants with OM during study period, n (%) | |
 CSOM | 7 (37%) |
 AOMwP | 4 (21%) |
 AOM | 1 (5%) |
 OME | 11 (58%) |
Participants with other ear symptoms during study period, n (%) | |
 Dry perforation |  |
 Eustachian tube dysfunction | 4 (22%) |
 Granular myringitis | 1 (5%) |
Participants with no OM or ear symptoms during study period, n (%) | 1 (5%) |
Participants receiving pharmaceutical treatment during study, n (%) | |
 Ciprofloxacin drops | 10 (53%) |
 Oral antibiotics | 9 (47%) |
Participants receiving surgical treatment during study, n (%) | |
 Grommet insertion | 5 (26%) |
 Adenoidectomy | 7 (37%) |